Brind.

Gilead Sciences appoints Mercier as CCO and responds to Winnie Byanyima's call for generics amid policy shifts influenced by RFK Jr.'s ruling.

1 report, 1 independent Updated Aug 9

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Gilead Sciences Mercier Robert F. Kennedy Jr.

Keep exploring

The entities involved

Gilead Sciences
American company
- FDA approved lenacapavir (Yeztugo) on August 18, 2025, solidifying the HIV portfolio for Gilead Sciences.Mon 18:04
- Dean Hakanson led U.S. Medical Affairs for the remdesivir launch and served in senior leadership positions at major pharmaceutical companies.Mon 17:32
Mercier
costume designer
- TAF's royalty obligation expiration boosted gross margin, and Mercier reported strong sales growth performance.Sat 21:47
Robert F. Kennedy Jr.
American politician, environmental lawyer, anti-vaccine activist, and conspiracy theorist (born 1954)
- DPH calls for Congress to investigate Robert F. Kennedy Jr. while Abdul El-Sayed is elected senator from Michigan.02:23
- The Office for Civil Rights released a report concerning HHS policy.Tue 21:57

Related events

Gilead Sciences is commercializing medicines in Europe, with Anu Osinusi as VP of Clinical Development and Cynthia Levy supporting IDEAL results for Livdelzi.Jun 17

Coverage

Newest first; wire copies grouped

Aug 9Pharmaceutical TechnologyGilead’s Yeztugo sales “ahead of expectations” following launch After Gilead Sciences was given the green light for Yeztugo (lenacapavir) in the US and Europe, CCO Johanna Mercier said it is “well ah